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Key Points 
• Metformin-associated lactic acidosis is a rare but potentially fatal adverse event. 
Incident comorbidities and lack of metformin dose-adjustment in renal impairment 
are important contributing and triggering factors. 
• We developed and implemented an automated alert with highly sensitive 
prospective screening for metformin prescriptions in renal impairment into the 
clinical information system of a tertiary care hospital. Local safety experts validated 
resulting alerts and issued specific recommendations that effectively prevented 
inappropriate metformin administrations in renal impairment. 
• The presented concept of “semi-automated” alerts can be applied to the prevention 
of further clinically and economically relevant medication errors. 
 
SUMMARY 
Purpose Overdosing of the oral antidiabetic metformin in impaired renal function is 
an important contributory cause to life-threatening lactic acidosis. The presented 
project aimed to quantify and prevent this avoidable medication error in clinical 
practice. 
Methods We developed and implemented an algorithm into a hospital’s clinical 
information system that prospectively identifies metformin prescriptions if the 
estimated glomerular filtration rate (eGFR) is below 60 ml/min. Resulting real-time 
electronic alerts are sent to clinical pharmacologists and pharmacists, who validate 
cases in electronic medical records and contact prescribing physicians with 
recommendations if necessary. 
Results The screening algorithm has been used in routine clinical practice for three 
years and generated 2145 automated alerts (about 2 per day). Validated expert 
recommendations regarding metformin therapy, i.e. dose reduction or stop, were 
issued for 381 patients (about 3 per week). Follow-up was available for 240 cases, 
and prescribers’ compliance with recommendations was 79 %. Furthermore, during 3 
years we identified 8 local cases of lactic acidosis associated with metformin therapy 
in renal impairment that could not be prevented, e.g. because metformin overdosing 
had occurred before hospitalization. 
Conclusions Automated sensitive screening followed by specific expert evaluation 
and personal recommendations can prevent metformin overdosing in renal 
impairment with high efficiency and efficacy. Repeated cases of metformin-
associated lactic acidosis in renal impairment underline the clinical relevance of this 
medication error. Our locally developed and customized alert system is a successful 
proof-of-concept for a proactive clinical drug safety program that is now expanded to 
other clinically and economically relevant medication errors. 
 
  
INTRODUCTION 
Metformin is primarily used as first line treatment for type 2 diabetes and the most 
frequently prescribed oral antidiabetic drug worldwide. Its efficacy and tolerability are 
well established.1 Because metformin is not metabolized but eliminated unchanged 
via the kidneys, it can accumulate in impaired renal function. These patients may 
develop metformin associated lactic acidosis (MALA), a severe adverse drug event 
with reported fatality rates of 25 - 50 %.2 Quantification of this risk is challenging and 
its relevance in clinical practice is subject of ongoing debates.3 The SPC of 
metformin states contraindications regarding its use in patients at an increased risk 
for lactic acidosis, e.g. alcoholics, severe infections, patients suffering from 
decompensated heart failure or severe impaired renal function with a glomerular 
filtration rate (GFR) below 30 ml/min. Since 2015, regulatory authorities in 
Switzerland and the EU allow the use of metformin in patients with mild to 
moderately impaired renal function if its dose is adapted accordingly and the GFR is 
regularly monitored, which is in line with many expert recommendations and common 
clinical practice.4,5 
Patients in a tertiary care hospital have a high prevalence and incidence of impaired 
renal function as well as further risk factors for MALA including comorbidities and 
administration of intravenous contrast agents. Failure to adapt metformin dosing in 
response to impaired renal function is a preventable medication error. If hospitals use 
electronic clinical information systems (CIS) data on patients’ metformin prescriptions 
and renal function are documented in a structured electronic format. This information 
can be linked and used for the automated systematic prevention of MALA. A 
proactive safety system must be efficient, effective and avoid overalerting. 
Recommendations to prescribers must therefore not only be highly sensitive, but also 
highly specific because clinically irrelevant alerts will not be accepted and may lead 
to alert fatigue and indiscriminate alert overriding.6 
 
Therefore the present study’s aim was the development, implementation and 
outcome analysis of a highly sensitive and specific automated alert for the prevention 
of metformin overdosing in hospitalized patients with impaired renal function. 
 
METHODS 
This proactive medication safety project was performed in a tertiary care hospital that 
provides medical care to a population of about 1.5 million people and has 
approximately 1000 beds and 40 clinical specialty divisions. It features a clinical 
information system (CIS) by Cistec AG with integrated laboratory data, computerized 
physician order entry (CPOE) and comprehensive electronic medical records.7  
We designed and implemented a sensitive automated algorithm that detected any 
metformin prescription entered through the hospital’s computerized physician order 
entry (CPOE), and for all metformin users the latest available estimated glomerular 
filtration rate according to the CKD-EPI formula (eGFR) was checked daily. If the 
eGFR in current metformin users was below 60 ml/min, an automated alert was 
immediately sent via the CIS’s internal email-system to clinical safety experts (SR, a 
clinical pharmacologist; DN and RK, clinical pharmacists). In a second step these 
highly sensitive alerts were then subject to a highly specific expert evaluation 
regarding their clinical relevance. For that purpose patients’ original medical records 
were reviewed not only for the latest prescribed daily metformin dose, but also for 
unstructured information including causes and circumstances of decreased eGFR, 
medical diagnoses and further risk factors for MALA. If the current metformin dose 
exceeded expert consensus, i.e. in-house recommendations supported by published 
guidelines,5 a personal alert with metformin dosing recommendations was issued to 
the prescribers via internal email and if deemed necessary also via telephone. The 
overall project design is presented as a closed-loop quality control system in Figure 
1. The project was first initiated in 2011 and is fully operational in its current form 
since 2012. For the years 2012 to 2014 we also retrospectively analyzed patients for 
whom an alert had been forwarded to the prescribers in order to evaluate the 
system’s acceptance by the prescribing physicians. The cantonal ethics committee, 
the hospital’s medical director and the hospital’s center for clinical research had 
approved the data extraction, the setup and analysis of the database and the access 
to original medical records for research purposes. 
 
RESULTS 
During three years since its implementation, the initial highly sensitive screening 
algorithm generated 2145 automated alerts to the local safety experts, i.e. 
approximately 2 per day. The subsequent daily evaluation of the alerts including 
review of the respective patients’ electronic medical records required approximately 2 
to 10 minutes per patient. Following this highly specific expert evaluation that 
included also non-structured medical information changes of metformin therapy were 
recommended for 381 cases (17.8 %), i.e. approximately 2 to 3 per week (Table 1). 
In order to evaluate the outcome of the system we also analyzed follow-up data, 
which was available for 240 patients. Among those, metformin dose had been 
reduced or stopped in 191 patients, corresponding to a compliance of 79 % with our 
recommendations. In case of non-compliance we found that there were typically only 
mild discrepancies between recommended and administered doses, e.g. 1700 
instead of 1500 mg metformin per day. 
In addition we were also able to search our local clinical records and databases for 
cases of MALA. From 2011 to 2014 we identified 8 cases of MALA in patients with 
renal impairment. They had all occurred in circumstances where no timely 
recommendation could have been generated, such as metformin overdosing before 
hospital admission. In all MALA cases we identified also other contributory and 
triggering causes and risk factors for lactic acidosis. While the overall number of 
alerts issued to the prescribers remained constant during three years, the number of 
any metformin prescription in patients with an eGFR < 45 ml/min and the number of 
patients with pronounced metformin overdosing declined from 2012 to 2014 (Table 
1). 
 
DISCUSSION 
There is an ongoing debate regarding the causal role of metformin in cases of lactic 
acidosis, and we realize that metformin overdosing is rather a contributory cause in 
patients with other acute conditions associated with hypoxia, than a single sufficient 
cause. However, regardless of the interaction of several contributing causes, there is 
no doubt that metformin aggravates any lactic acidosis, that its dose must be at least 
reduced in moderate to severe renal impairment, and that particularly in patients with 
several risk factors for lactic acidosis metformin must be stopped. The observed 
cases of MALA, some with metformin doses clearly exceeding current 
recommendations, underline that the issued alerts address a clinically relevant 
adverse drug event. 
The presented proactive drug safety project against metformin overdosing in 
impaired renal function applied an innovative 2-step approach, hence called “semi-
automated”. First, a highly sensitive fully automated screening algorithm identified 
any current metformin users with an eGFR below 60 ml/min. It is important to note 
that this ongoing daily screening algorithm also detects patients with a normal eGFR 
at the time of the first in-hospital metformin prescription when the eGFR later 
decreases below this threshold during hospitalization. In a second step local clinical 
safety experts performed a highly specific expert review that is difficult to automate 
because also unstructured medical information and the latest specific situation of 
individual patients have to be considered. However, the initial screening was a 
necessary prerequisite in order to increase the system’s efficiency. Even with limited 
resources, i.e. approximately 5 minutes per patient, it was then possible to evaluate 
on average two patients per day that the screening algorithm had detected. The 
compliance of 79% indicates that such a combined system can provide a solution for 
a major challenge that current clinical decision support systems face. For most 
potential medication errors only the additional consideration of unstructured medical 
information and clinical expertise can increase the specificity of an alert to a level that 
does not cause alert fatigue and non-compliance of prescribing physicians. Therefore 
the current project is also an important proof-of-concept for an approach that can 
reach high efficiency and efficacy in clinical practice and is yet easy to implement 
with limited resources. Furthermore, the decrease regarding metformin overdosing in 
the most vulnerable patients with an eGFR < 45 ml/min suggests that such a system 
may also have an educative effect and thereby contribute to an increased awareness 
of local prescribing physicians.  
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Figure 1: Study flowchart of semi-automated alerts 
 
see separate graphic file 
Table 1: Metformin prescriptions in patients with eGFR < 60 ml/min and subsequently issued alerts  
 
Year 
Automated 
alerts to safety 
experts 
Expert alerts 
to prescribers 
Patients with 
available follow-up 
Sex 
m / f 
Mean age 
eGFR 31 - 44 ml/min 
at time of alert 
eGFR < 30 ml/min 
at time of alert 
Overdose ≥ 1000 mg 
compared to recommended 
dose at time of alert 
Compliance 
n           % 
2012 643 135 90 57 / 33 73 41 16 52 81 90.0 
2013 693 123 88 51 / 37 72 30 13 36 67 76.1 
2014 809 123 62 40 / 22 74 19 7 24 43 69.4 
 
 
